Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.7164 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.7164 | 0.7164 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.7164 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.4037 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.7164 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.7164 | 0.7164 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.4037 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.4037 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.4037 | 0.5 |
Brugia malayi | hypothetical protein | 0.0043 | 0.7164 | 0.6687 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.4037 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.4037 | 0.5 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.7164 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.4037 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.7164 | 0.7164 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.7164 | 0.7164 |
Brugia malayi | hypothetical protein | 0.003 | 0.4037 | 0.3031 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 1 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.4037 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 5.6234 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 6.5131 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 112.2018 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.